While, for instance, efficacy of PARP inhibitors was largely restricted to HR-deficient ovarian and breast tumors [122] recent studies proposed also a synergistic impact of ATR inhibitors to overcome PARP inhibitor resistance [123]. The gene discussed is ATR; the disease is breast neoplasm.